Aktienanalyse zu Annexon, Inc. (ANNX)ANNXAnnexon, Inc.

Annexon, Inc. is a biopharmaceutical company advancing targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Tanruprubart is an investigational-targeted immunotherapy delivered in a single infusion to rapidly halt aggressive neuroinflammation and damage in GBS, an acute, rare, neuromuscular emergency. The Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness. ANX1502, a novel oral small molecule for autoimmune conditions. The Company's next wave programs include ANX005 and ANX009. ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Annexon Inc is a good buy right now due to its current price of $3.41, which is significantly below the analyst price targets of $15 and $25, indicating substantial upside potential. Additionally, the stock is currently oversold with an RSI of 12.471, suggesting a potential rebound. The main risk is the company's ongoing net losses, which totaled $55.3 million in Q2 2026, reflecting high expenditures in R&D and operations.